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Abstract
Long non-coding RNAs (lncRNAs) are transcripts that are over 200 nucleotides and do not encode
proteins. LncRNAs are involved in a wide spectrum of biological processes ranging from cell
proliferation, apoptosis, and nutrient sensing to cell differentiation. Further, lncRNAs have been
reported to play an important role in a wide range of pathophysiological processes and are linked
to diseases such as cancer. Thus, lncRNAs are becoming increasingly important as biomarkers to
study biological and disease processes. In our work, we develop a DNA nanoswitch-based assay
for detecting long RNAs. The DNA nanoswitch is a reconfigurable device that undergoes a
conformational change from a linear “off” state to a looped “on” state upon interaction with the
target molecule. The two states can be easily identified on an agarose gel. Using in vitro transcribed
RNA controls, we optimize the assay for detecting different lengths of target RNAs, validate the
sensitivity and specificity of the assay, and detection of target RNA in the presence of total RNA
extract. Our work aims to create a lncRNA detection assay that will be useful in the early treatment
of diseases and in screening potential biomarkers (for example, in Duchenne Muscular Dystrophy).
The DNA nanoswitch-based assay is low-cost, highly sensitive and specific, and easily adaptable
in any laboratory for detecting various biomarkers.
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Introduction
Biomarkers and their importance
According to the Food and Drug Administration (FDA), a biomarker is a “defined characteristic
that is measured as an indicator of normal biological processes, pathogenic processes, or responses
to an exposure or intervention, including therapeutic interventions”.1 The determination of various
biomarkers is important to understand the pathophysiology of organisms. Their realization will
lead to the development of diagnostic testing and possible therapeutics for medical conditions.
Biomarkers can be grouped as histologic, radiographic, physiologic, or molecular.1 Histological
biomarkers are represented as biochemical/molecular alterations of cells, tissues, or fluid samples
at various stages.2 For example, histological biomarkers may be representatives of the stages of
tumors for cancers. Radiographic biomarkers are those obtained through radio-imaging.2 An
example of this is the size of a tumor as a cancer progresses. Physiological biomarkers are
measures of the body processes, such as blood pressure. Molecular biomarkers are those with
biophysical properties which are measurable in a biological sample; a simple example of this is
blood glucose level. Molecular biomarkers have the potential to increase the robust nature in which
diagnoses are made and treatments are studied and developed. As medicine moves towards a more
individualistic basis of treatment, the molecular level will become increasingly important to
determining diseased states or conditions early on in development as well as the potential treatment
options for a patient. For instance, miRNAs have been shown to be differentially expressed in the
blood of cancer patients and could serve as a molecular indicator of the diseased state.3
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lncRNAs as biological markers
LncRNAs are RNA transcripts exceeding 200 nts in length that do not code for proteins.4,5 Their
expression in mammalian tissue has been studied increasingly over recent years.6 Of the lncRNAs
discovered, many are regulators of gene expression and modulators of epigenetic states.7,8
LncRNAs are involved in a variety of biological pathways inclusive of cancer pathways,9,10
hypertension,11 cardiometabolic diseases,12 stroke,13 and epigenetic splicing events.14

As more information emerges surrounding the world of lncRNAs, the quantification of known
lncRNAs has been somewhat lacking.15,16 Previous analysis of lncRNA expression found that
lncRNAs may be present in low levels in bulk tissue samples but in higher levels in individual
cells.17 The difficulty in detection is notable because identification of specific lncRNAs may be
varied as the copies present per cell may be few or specific to only certain cells. Further, lncRNAs
may be characterized by the presence or lack of polyadenylated tails18 which may limit
quantification using popular techniques such as RNA sequencing. This may also complicate
lncRNA discovery as non-coding regions possessing polyadenylated caps suggest some protein
coding function or mutation in mRNA sequences.

So far, lncRNAs have been detected using microarrays, qPCR, and Next Generation Sequencing.19
These detection methods, while showing high sensitivity and specificity, are costly, requiring
expensive equipment and skilled personnel. Some of these methods also provide indirect
quantification of lncRNAs increasing variation in the actual proportions in total RNA. Thus,
newer, alternate methods that can provide low-cost and direct detection of lncRNAs are needed.
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DNA nanotechnology-based biosensing methods
Beyond the traditional methods such as PCR, microarrays and Next Generation Sequencing, the
field of DNA nanotechnology has been booming with methods to detect, sense and quantify
various biomolecules.20,21 In DNA nanotechnology, DNA is used as a material to construct various
shapes and structures in the nanoscale.22–24 These structures have been used in applications such
as biosensing,20 drug delivery,25 cell modulation,26 molecular computation,27 and data storage.28
DNA devices developed for biosensing include DNA-PAINT (DNA-based points accumulation
for imaging in nanoscale topography) used for 3D imaging and quantifications of proteins,29 ISwitch for pH-detection,30 DNA polyhedra for nucleic acid detection,31 and DNA origami-based
structures for detecting antigens.32 In our lab, we have developed DNA nanoswitches to detect
several biomarkers such as microRNAs, viral RNAs, enzymes and antigens.

DNA nanoswitches – Design, operation and read out
The DNA nanoswitch is a biosensing device comprised of a linearized single stranded (ss) M13
scaffold (7249 nucleotides) made double stranded by annealing short complementary backbone
oligonucleotides (Figure 1a) that are 49-60 nt each.33–35 Two of these backbone oligos are modified
to contain single stranded extensions (detectors) that are complementary to parts of the target RNA.
The constructed nanoswitch is said to be in a linear “off” state. Upon binding a target nucleic acid,
the nanoswitch undergoes a conformational change from the linear “off” state to a looped “on”
state (Figure 1a). Binding of the target RNA to the detectors can be visualized by agarose gel
electrophoresis (Figure 1b). The nanoswitches are stained using regular DNA gel stains (Gel Red
in this case) providing a direct readout. As the samples run through the gel, the “on” nanoswitches
run slower through the pores of the gel compared to the “off” nanoswitches (indicated by the two
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bands in the experimental lane referred to as positive (+) in Figure 1b). This assay, compared to
the previously discussed methods of PCR, Microarrays and Next Generation Sequencing, is quick,
low cost and adaptable for bench top experimentation in most lab settings.

a

b

Figure 1. DNA nanoswitch design, operation and read out
(a) The DNA nanoswitch consists of a linear M13 single strand hybridized to backbone
oligonucleotides two of which are modified to contain single stranded extensions (detectors).
These extensions are designed to be complementary to parts of the target RNA. When both
detectors base pair with the target the nanoswitch undergoes a conformational change from the
linear (off) state to a looped (on) state. (b) The results of this conformational change may be
visualized on an agarose gel where the “on” nanoswitches migrate differently on the gel compared
to the “off” nanoswitches.
In previous work, our lab has used the DNA nanoswitches for detecting nucleic acids,36–38
antigens,39 and ribonucleases.40 For nucleic acids, we have shown detection of microRNAs
(miRNAs). MiRNAs are short sequences of RNA, approximately 22 nucleotides (nt) in length that
do not encode proteins.21 They are known to regulate gene expression post transcriptionally
through antisense binding to messenger RNA (mRNA).41 In our lab, we have developed a
nanoswitch based assay for the detection and quantification of miRNAs specific to skeletal muscle
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differentiation38 and Alzheimer’s Disease (AD)37 using a microRNA activated conditional looping
of engineered switches (miRacles) assay. Alzheimer’s Disease, AD, a neurodegenerative disorder,
has been studied for many years to achieve early detection and treatment options for individuals
currently with and those pre-disposed to the development of AD. Further work in our lab on ADassociated miRNAs showed variable levels of specific miRNAs in total RNA isolated from
different regions of the brain, showing dysregulation in healthy versus diseased samples.37 The
importance of this is profound as these miRNAs have the potential to assist in the development of
non-invasive diagnostic methods for AD, therapeutic treatments and increased understanding of
the disease.

In addition to our study of AD which has had chronic impacts on the aging population, our lab has
also achieved rapid detection of the more acute SARS-CoV-2, a viral RNA.36 Viral RNAs are long
pieces of RNA originating from RNA viruses. These viruses invade living cells and utilize the
transcriptional machinery of the host to mutate, increasing the viral RNA load. As such, viral
RNAs are molecular biomarkers which may indicate the existence and progression of an infection.
This is the RNA virus that caused the COVID-19 pandemic we continue to experience today. The
detection of SARS-CoV-2 RNA has been achieved commercially through RT-PCR, where a
sample of the RNA transcript is isolated through a nasopharyngeal swab and reverse transcribed
followed by which the sample undergoes PCR for quantification and determination of a positive
or negative COVID-19 result. This method is expensive, taking place at commercial labs
predominantly and somewhat time intensive. As such, our lab developed a 35–55-minute approach
for the direct detection of SARS-CoV-2.36 Rapid detection has the potential to reduce spread of
the disease. We have also previously shown viral RNA detection for Zika and Dengue viruses,
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also plaguing our communities.36 Biomarkers are important and furthermore, the study of nucleic
acid biomarkers like these and lncRNAs are integral to developing a deeper and more
comprehensive understanding of the genetic mechanisms of the human body and how we treat
certain diseases.
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Materials and Methods
Linearization of M13 DNA
We obtained circular M13mp18 single-stranded DNA (New England Biolabs, cat. no. N4040S)
and verified the concentration using the Nanodrop. Following this, we prepared 100 µl batches of
linearized M13 by mixing 20 µl of circular M13 DNA, 10 µl of 10x cutsmart buffer (New England
Biolabs, cat. no. B7204S; included with BtsCI enzyme purchase), 4 µl of cutsite oligo (Integrated
DNA Technologies, IDT) and 66 µl of nuclease free water (ultrapure distilled water, DNase, and
RNase free, Invitrogen, cat. no. 10977-015). BtsCI enzyme can only cleave double-stranded DNA,
as a result of this, the cutsite oligo was needed to make the M13 DNA double stranded so the
cleavage was possible.

This mixture was collected into a PCR tube and annealed in a thermocycler by heating to 95 ºC
and cooling to 50 ºC. At this temperature, 4 µl of BtsC1 restriction enzyme (20,000 U/ml; New
England Biolabs, cat. no. R0647S) was added. We pipetted the mixture thoroughly using a 100 µl
pipette. The annealing protocol was resumed, and the mixture was incubated at 50 ºC for 15
minutes. After the additional incubation period, the sample was reheated to 90 ºC (to denature the
enzyme) and cooled to 4 ºC. The 100 µl mixture of linearized M13 was then stored in a -20 ºC
freezer.35
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Figure 2. DNA nanoswitch construction, purification, and detection
The DNA nanoswitch is constructed from a BtsCI linearized ssDNA M13 scaffold which has been
annealed with backbone oligonucleotides and detector strands specific to a target. These
nanoswitches are purified using high performance liquid chromatography to remove excess
oligonucleotides. The nanoswitch is validated upon incubation with the target where it undergoes
a conformational change that is visualized and analyzed through agarose gel electrophoresis.
Reproduced from ref.38

DNA nanoswitch construction
The DNA nanoswitch was formed by annealing the linearized M13 DNA to a mixture of backbone
oligonucleotides and detector strands following protocols previously established in the lab (Figure
2).38 Linearized M13 was mixed with 10x molar excess of complementary backbone
oligonucleotides and detector strands. The mixture was then annealed using a temperature ramp
from 90 ºC to 25 ºC at 1 ºC/min. Annealed DNA nanoswitches were purified from excess
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oligonucleotides using high performance liquid chromatography (HPLC) with methods we
previously established.42

Preparation of in vitro transcribed (IVT) RNA
As an experimental control for long RNAs, we prepared a 1260 nt RNA by in-vitro transcription
using RNA Clean & Concentrator-25 kit (Zymo Research, Cat# R1017). The control template was
mixed with T7 polymerase mix, 900 µg/ml of PVSA (Polyvinyl sulfonic acid), NTP Buffer mix
and nuclease free water. The mixture was transcribed at 37 ºC for 2 hours following which it was
treated with DNase I (2000U/ml). Incubation at 37 ºC was resumed for an additional 15 minutes.
The IVT RNA was precipitated by incubation with LiCl at -80 ºC for 60 minutes. Following this,
the sample was transferred to a 1.5 ml tube and centrifuged (10,000 g) for 15 minutes to pellet the
IVT RNA. The supernatant (LiCl and other contaminants) was removed, and the pellet was washed
with 500 ml of iced 70% ethanol. The sample was centrifuged (10,000 g) for 5 minutes and the
ethanol was removed. The pellet was left to dry following which the sample was resuspended in
100 µl of nuclease free water. The concentration was determined using the Nanodrop
spectrophotometer. IVT RNA was stored at -80 ºC.

DNA nanoswitch assay
DNA nanoswitches were validated by incubating them with synthetic target DNA. 100 µM stock
concentration of the DNA was made per manufacturer’s sheet. Following this, the actual
concentration was ascertained using a Nanodrop spectrophotometer and then dilutions of the target
DNA were made at 1 µM and 25 nM. DNA nanoswitches were tested using the 25 nM target to
determine whether they worked by mixing 1x final of PBS, 10 mM MgCl2, nuclease free water,
DNA nanoswitches and synthetic target DNA in a 10 µl reaction. Negative controls were done by

9

replacing the DNA target with nuclease free water. All samples were incubated for a minimum of
30 minutes at various incubation temperatures, then mixed with Gel Red and loading dye, and run
on a 0.8% agarose gel for 45 minutes at 75 V.

Agarose gel electrophoresis
0.8% agarose gels in 0.5x TBE buffer (Tris Boric EDTA) were made. Unless otherwise specified,
samples of nanoswitches with targets and their respective controls were mixed with Gel Red and
6x loading dye (Ficoll based loading dye with Bromophenol blue) to a final 1X concentration.
10µl of this reaction mixture was loaded into each well. Gels were typically run at 75V for 45
minutes at room temperature. All gels were imaged using Image Lab software and the bands are
quantified.

RNA Fragmentation
We fragmented the invitro transcribed long RNA using 5xTris HCl fragmentation buffer consisted
of 15 mM MgCl2 and 100 mM Tris-HCl at a pH of 8.5. We carried out fragmentation by mixing
long RNA with the fragmentation buffer (at a final of 1x) and nuclease-free water. Following the
set-up of the reaction mixture, we heated the samples at 94 ºC for various time points from 0
minutes to 64 minutes to fragment the RNA.

Detection of fragmented long RNA
We designed DNA nanoswitches to target a specific region of the long RNA. The long RNA was
mixed with either buffer (1x final) in a 5 µl reaction for fragmentation. Samples were fragmented
at 94 ºC for 0, 2, 4, 8, 16, 32, and 64 minutes. Following fragmentation, 1 µl of the fragmented
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samples were mixed with 1 µl of HPLC purified DNA nanoswitches, 2 µl of a 5x incubation buffer
and 6 µl of nuclease free water. The 5x incubation buffer was created as a standard mix of 1 µl of
5% SDS, 3 µl of 1 M MgCl2, 2 µl of 100 µM blocking oligo and 13 µl of nuclease free water. All
samples were incubated for 110 minutes at 50 ºC in a thermocycler. 5 µl of 100 mM EDTA was
added, and incubation resumed for an additional 10 minutes. All samples were then treated with
1:2 loading mixture (1:1000 dilution of Gel Red and 6x loading dye diluted in 5 µl of nuclease free
water). 8 µl of the sample was run on a 0.8% agarose gel.

Detection in the presence of total RNA
We spiked in the in vitro transcribed Long RNA into murine skeletal muscle total RNA (Biochain,
cat. no. R1334171-50). The long RNA was fragmented in 5x Tris-HCl and 1 µl of the fragmented
RNA (1 ng/µl) was added to the total RNA to test detection. Negative and positive controls were
done in buffer (final reaction concentration of 1x PBS and 10mM MgCl2 (no total RNA) with the
negative control having no DNA target and the positive control having the DNA target. The DNA
nanoswitch detection assay was then performed on the buffer controls as well as the spiked in
samples of the total RNA.
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Results and Discussion
As a first step towards the detection of long non-coding RNAs, we made long RNA using in vitro
transcription. In vitro transcription was done so we would have a template for assay optimization
tests as long non-coding RNAs are precious. We tested the concentration of the in vitro transcribed
long RNA using a Nanodrop spectrophotometer to ensure it was suitable for optimization tests.
Some of the concentrations obtained from various transcriptions were 41.2 ng/µl, 131.8 ng/µl,
120.5 ng/µl, and 136.7 ng/µl. An aliquot of each of these samples was taken to achieve a pooled
sample concentration of 109 ng/µl. To validate proper in vitro transcription, we tested one of the
samples on a 0.8% agarose gel along with a single stranded RNA (ssRNA) ladder (Figure 3). The
migration of the long RNA band matched the expected length of the transcribed RNA (1260 nt),
migrating between the 1000 nt and 2000 nt bands of the ssRNA ladder. This indicated a proper
IVT reaction. Since the sample of long RNA was run on a native, nondenaturing agarose gel, the
upward smear bands are indicative of possible secondary structures of the long RNA.
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ssRNA
ladder

Long
RNA

2000 nt
1000 nt

1260 nt

Figure 3. Characterization of long RNA
The long RNA was run on a 0.8% agarose gel. The band corresponding to the long RNA migrated
at the range between the 1000 and 2000 nt bands of a ssRNA ladder, indicating proper IVT of the
1260 nt RNA.

To test detection of the target RNA, we first constructed nanoswitches that were specific to a 60
nt region of the long RNA. We validated the nanoswitches by incubating them with a 60 nt
synthetic DNA target, analogous to the targeted sequence of the long RNA (Figure 4a). We
incubated the nanoswitches with 25 nM of the synthetic DNA target and confirmed working of the
nanoswitches on an agarose gel (Figure 4b). The presence of the “on” band in the gel indicated
that the nanoswitch detectors bound the target and reconfigured into the looped state.
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a

b

DNA targets

-

+

target region

on
off

long RNA

Figure 4. Depiction of long RNA and run of DNA target with DNA nanoswitch
(a) Depiction of long RNA (pink) with the target region in red. (b) Agarose gel showing
reconfiguration of the nanoswitch in the presence of target DNA. The (+) and (-) indicate presence
or absence of the target.
In previous work on detecting viral RNAs, the target RNA (~11,000 nt) was fragmented to achieve
detection using DNA nanoswitches. Based on those results, we fragmented the long RNA by
heating it at 94 ºC in 5xTris HCl buffer for different time points. Results showed that the size of
the fragments decreased with increasing fragmentation time as seen by lowered-mobility bands on
the gel during the time course (Figure 5). As heat fragmentation is random, the target region may
be randomly cleaved and even fully degraded decreasing their detection potential. As such, we
designed and constructed nanoswitches with variable detector lengths to address this (Figure 6a).
To test the nanoswitches, we incubated them with a 60 nt DNA target at 20 ºC and at 50 ºC for 1
hour. Results showed that samples incubated at 50 ºC yielded higher detection signals than the
samples incubated at 20 ºC as the bands were more visible on the gel after imaging (Figure 6b).
These results indicated that the higher incubation temperature was well-suited to the base pairing
14

of the DNA target sequence with the detectors of the DNA nanoswitches. Further, the variability
in detection among DNA nanoswitches of variable detector lengths may be attributed to complete
base pairing versus incomplete base pairing of sequences.

Fragmentation Time (min)
0

1

2

4

8

16

32

64

Fragment siz
e

Long RNA

Figure 5. Fragmentation of long RNA at increasing fragmentation time points
As shown by the triangular grey bar on the side, the size of the fragments decreases with increasing
fragmentation time.
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50 ºC incubation

off

25 nt

30 nt

Detector length (nt)
15
-

15
+

20
-

20
+

25
-

25
+

30
-

30
+
on

Room
temperature
incubation

off

Figure 6. Detector length illustration and incubation temperature tests
(a) Illustration showing nanoswitches with 15 nt to 30 nt long detectors. The 15 nt nanoswitches
can bind to a total of 30 nts of the target sequence while the 20 nt detectors would bind a total of
40 nts of the target sequence and so forth. Color code (green = detector strands, pink = M13
scaffold, blue = backbone oligonucleotides). (b) Nanoswitches with different detector lengths
incubated with DNA targets at 50 ºC (top gel) and room temperature (bottom gel) for 1 hour.
Detection signal increased for 20, 25 and 30 nt detectors under 50 ºC incubation. Visible detection
was achieved for 30 nt detector nanoswitches at room temperature.

Next, we fragmented our long RNA using a 5x Tris HCl fragmentation buffer made in-house (the
buffer is a mixture of 15 mM MgCl2 and 100 mM Tris-HCl at a final pH of 8.5). We set up
fragmentation with the long RNA and Tris HCl fragmentation buffer (1x final). Following long
RNA fragmentation, we incubated the DNA nanoswitches with the fragmented long RNA at 50
ºC for a total of 2 hours. The results obtained showed no visible detection of the fragmented long
RNA with the 15 nt detector DNA nanoswitches (Figure 7). The 20 nt detector nanoswitches
showed visible detection with long RNAs fragmented for 2 to 16 minutes. The brightest detection
signals were determined to be from long RNA fragmented for 8 and 16 minutes with the 30 nt
detector nanoswitches (indicated by the red box in Figure 7).
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5x Tris HCl fragmentation buffer
Fragmentation time (min)
-

+

0

1

2

4

8

16

32

64

15 nt

on
off

20 nt

on
off

25 nt

on
off

30 nt

on
off

Figure 7. Detector length and 5x Tris HCl fragmentation time course
The bands were quantified in image lab and the results showed the brightest and most uniform
bands at 8- and 16-minute fragmentation (boxed in red).
Next, we determined the detection limit of our 30 nt detector DNA nanoswitches by testing
detection of different concentrations of long RNA fragmented with 5xTris HCl buffer. We
incubated the 30 nt detector DNA nanoswitches with increasing amounts of long RNA fragmented
at 8 minutes. The incubation conditions were set to 50 ºC for 1 hour and 50 minutes followed by
the addition of 5µl of 100 mM EDTA. The samples were incubated for an additional 10 minutes.
After imaging, we determined visible detection at 18.8 pM or 62.5 pg of fragmented RNA (Figure
8a and 8b).
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a

Amount of RNA (pg)

Amount of RNA (pg)
NC

15.6 31.3 62.5 125 250 500 1000
on
off

Concentration of RNA (pM)
NC

4.7

9.4

18.8

37.6

75.3

150.5

301.0

NC

15.6

31.3

62.5
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Looped band intensity (au)

b

Amount of RNA (pg)

Figure 8. Concentration series detection of long RNA
(a) Gel image showing detection of different amounts of long RNA. Visible detection was achieved
at 62.5 pg. (NC = negative control where no RNA is present). (b) Graph showing the quantification
of the “on” bands in (a) (au = arbitrary units).
We further tested the ability of our nanoswitches to detect the fragmented long RNA in the
presence of total RNA (Figure 9). We did tested detection in the presence of unfragmented total
RNA by incubating the DNA nanoswitches in buffer with and without a target DNA sequence
(positive and negative controls, respectively) to ensure the nanoswitches were functional. Then we
set up three samples for incubation of DNA nanoswitches with 500 ng/µl total RNA obtained from
murine skeletal muscle cells: (1) 25nM of the DNA target spiked into the total RNA as an
additional control to determine the location of the looped band on the gel in the presence of
unfragmented total RNA, (2) the nanoswitch only in the total RNA, and (3) 1 ng/µl fragmented
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long RNA spiked into the unfragmented total RNA. Our results showed that the nanoswitch was
able to detect the fragmented RNA in the presence of unfragmented total RNA (Figure 9, lane 5).
Further, this detection was specific to detect the target RNA in a biological sample mimic as there
was no unspecific binding or false positive results (shown in total RNA and nanoswitch only gel
lane, Figure 9, lane 4). As future steps, nanoswitches specific to known lncRNAs are being
designed and will be tested by fragmenting total RNA to increase the detection signal in
accordance with our current assay and limit the formation of complex secondary structures. The
fragmented total RNA will be incubated with DNA nanoswitches to test detection.
2

5

Total RNA

+

Fragmented
RNA

−

4

Nanoswitch

Buffer

3

Spiked in
DNA

1

on
off

total RNA

Figure 9. Detection in the presence of total RNA
From left to right: (1) Negative control in buffer, (2) positive control in buffer, (3) DNA target
spike-in in the presence of total RNA, (4) DNA nanoswitch only in total RNA, (5) fragmented
RNA spiked into total RNA. The “on” band indicating detection is shown by the yellow arrow on
the right. The shift of the bands in lanes 3-5 is due to the additional RNA present in total RNA
causing additional drag of the DNA nanoswitches through the gel.
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Conclusion
DNA nanoswitches are biosensing devices that can be utilized for the detection of nucleic acids
including miRNAs and viral RNAs. Here, we report a simple, low-cost strategy for the detection
of long RNAs in a bench-top laboratory setting as a blueprint towards the detection of lncRNAs.
Our strategy utilizes heat fragmentation (1x Tris HCl buffer at 94 ºC) to fragment long RNAs
which increases the detection signal of our assay. Due to the random nature of fragmentation, we
utilized the programmable nature of our DNA nanoswitches to create nanoswitches with variable
detector lengths ranging from 15 nt to 30 nt. The results of our assay showed that 30 nt detector
nanoswitches yielded the brightest detection signals for the detection of 8- and 16-minute
fragmented long RNAs at 50 ºC incubation.

Further, we have shown that our nanoswitches are sensitive to low concentrations of fragmented
long RNA where we achieved visible detection of 62.5 pg of fragmented long RNA. We also
showed that our nanoswitches were target specific when we tested our assay in the presence of
total RNA. As we go towards the detection of lncRNAs, our next steps include designing DNA
nanoswitches specific to known lncRNAs and then testing for detection in cell- or tissue-specific
total RNA. Following initial detection of lncRNAs present in total RNA would be optimization
tests to increase detection signals. Our nanoswitch assay has the potential to add to the existing
strategies for lncRNA detection, providing an efficient and affordable alternative for the detection
of lncRNAs as potential biomarkers for various conditions and diseases.
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